Scynexis (SCYX) Cash from Operations Growth (1y) (2014 - 2026)
Scynexis (SCYX) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.88 Bn | 32.14 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.64 Bn | 30.70 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.04 Bn | 20.88 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.37 Bn | 18.57 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.45 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 425.00% |
| 10 | Scynexis | 23.06 Mn | -13.69 Mn | - | -8.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.52% |
| Dec 31, 2025 | 285.74% |
| Sep 30, 2025 | -1,240.39% |
| Jun 30, 2025 | 30.99% |
| Mar 31, 2025 | -86.30% |
| Dec 31, 2024 | -28.08% |
| Sep 30, 2024 | -93.84% |
| Jun 30, 2024 | -114.60% |
| Mar 31, 2024 | 78.82% |
| Dec 31, 2023 | 66.08% |
| Sep 30, 2023 | 155.18% |
| Jun 30, 2023 | 500.40% |
| Mar 31, 2023 | -18.36% |
| Dec 31, 2022 | 10.63% |
| Sep 30, 2022 | -35.70% |
| Jun 30, 2022 | -58.88% |
| Mar 31, 2022 | -2,006.46% |
| Dec 31, 2021 | -53.99% |
| Sep 30, 2021 | -68.06% |
| Jun 30, 2021 | -32.06% |